Our website will soon be relaunched with a fresh look and improved user experience. Take a look by visiting our test site.
Call us 24/7 at (888) 552-6760
Cancer Treatment Centers of America


CTCA Lung Cancer Center
in Chicago

"Our team is ready to guide you through the difficult road of cancer treatment in the same compassionate and understanding way we would do for our own family."

Your treatment options

The Lung Cancer Center at Cancer Treatment Centers of America® (CTCA), Chicago, is designed to bring together a wide array of medical professionals devoted to diagnosing patients who have had test results that suggested they may have lung cancer, while also treating and assisting patients who have already been diagnosed with the disease. Our team of cancer experts, led by Medical Oncologist Dr. Bruce Gershenhorn, is committed to helping you make informed decisions about the options available to treat your disease and manage the side effects that may result.

Having a team of lung cancer experts collaborating daily, all under one roof, allows us to design a detailed treatment plan tailored to your tumor type, stage, genomic markers and other needs more quickly and efficiently. In this era of precision and personalized medicine, and based on your specific needs, our lung experts look to incorporate new and emerging treatments and technologies—including genomic-based cancer care, immunotherapy and targeted drug therapy—into every aspect of your treatment plan.

Our Lung Cancer Center doctors

Our oncologists, surgeons, interventional pulmonologists and supportive care clinicians are committed to helping you understand the complexities of your disease and the array of treatment options available to you, so you can make informed decisions about your care. The experts at the CTCA® Lung Cancer Center in Chicago have combined expertise in delivering standard-of-care and advanced techniques for treating lung cancer.

The Lung Cancer Center is led by board-certified Medical Oncologist Dr. Bruce Gershenhorn, who completed a fellowship at Montefiore Medical Center in Bronx, New York, where he served as Chief Fellow in the Department of Hematology/Oncology. He has authored several publications that have appeared in peer-reviewed publications, including Cancer Discovery and International Journal of Clinical and Experimental Pathology.

Working with Dr. Gershenhorn and the Lung Cancer Center team is Medical Oncologist Dr. Revathi Suppiah, who completed her residencies at University of Missouri-Columbia School of Medicine and Wayne State University/Sinai-Grace Hospital, then finished her fellowship at Cleveland Clinic Foundation.

Interventional Pulmonologists Dr. Yiping Fu and Dr. Abdul Hamid Alraiyes work together to provide advanced diagnostic and therapeutic techniques for patients with lung cancer, airway disorders and pleural diseases. Dr. Fu, who completed his critical care and pulmonary fellowship at the University of Chicago Hospital, has over 20 years of experience, and is board certified in critical care medicine, pulmonary disease and sleep medicine and interventional pulmonology. Dr. Alraiyes completed his interventional pulmonology fellowship at the Cleveland Clinic Foundation, and is board certified in internal medicine, critical care medicine, pulmonary medicine and sleep medicine.

Read more about these doctors and the rest of the Lung Cancer Center team below.

A comprehensive team approach

The clinical team working with our patients in the Lung Cancer Center are part of a wider team of multidisciplinary cancer experts who work together, collaborating daily with the patient and one another, all under one roof. Theirs is a synergy that comes from combining years of expertise and varied skills toward a single cause—treating lung cancer patients.

Each patient’s Lung Cancer Center care team is led by a medical oncologist and coordinated by a care manager, who is devoted to the many details needed to help patients achieve their treatment goals and maintain their quality of life. Our lung cancer pathologists also play a key role in diagnosing and staging the disease, to better pinpoint the treatment options available.

Various other doctors and clinicians may be assigned to your care team to help you meet your treatment goals and manage lung cancer-related side effects. For example, depending on your lung cancer type, stage and recommended treatment plan, your care team may include radiation oncologists, interventional pulmonologists, oncology nurses and a host of supportive care clinicians, all joining together to design a personalized care plan with a commitment to comprehensive care.

Quality of life

Conventional treatments plus supportive therapies
Evidence-informed data and patient feedback tell us that lung cancer patients often experience treatment-related side effects both during and after treatment, including fatigue, appetite loss, pain, nausea or neuropathy. To help you manage these and other side effects and maintain your strength and stamina throughout treatment and beyond, your team may also include various supportive care experts, including a dietitian, naturopathic provider, chiropractor, physical therapist, chiropractor, mind-body therapist, spiritual counselor and pain management provider.

Learn more about how integrative cancer care may help you manage your lung cancer journey.


Our 4-day lung nodule diagnosis program

Lung cancer is the second most common non-skin cancer among American men and women, after prostate cancer in men and breast cancer in women. Patients have more treatment options when the disease is diagnosed in its early stages than when it has advanced to later stages. We know the stress and uncertainty that comes with news that an X-ray or CT scan has revealed an abnormal spot on your lung. One of the first things you’ll need to know is if the suspicious mass or nodule is cancerous or benign. Getting a fast, accurate diagnosis is essential to your peace of mind, and your future care, no matter the result. The Lung Cancer Center team of cancer experts understands that time is of the essence and works quickly to provide a diagnosis—in as few as four days—and, if necessary, a treatment plan that meets your needs. Our lung cancer experts have designed a four-day diagnostic program, because they want their patients to get the comprehensive care they need more quickly.

Lung cancer clinical trials

Our Lung Cancer Center in Chicago is dedicated to offering innovative, leading-edge treatment options. One way to do that is by offering carefully selected lung cancer clinical trials in areas like immunotherapy, interventional pulmonology and chemotherapy. Clinical trials are an essential testing ground for measuring the effectiveness of drugs and other treatments before they can win FDA approval. Trials may offer participants new options that would otherwise be unavailable to them. See our Clinical Trials Q&A to learn more. Find out about the various lung cancer trials underway at CTCA.

Clinical trials Q&A

Are they only available to patients who have exhausted other lung cancer treatment options?

Lung cancer patients may qualify to participate in a clinical trial at any stage of their treatment journey. Some patients may join a clinical trial when they first start treatment, in conjunction with standard therapy, on the chance it may offer improved outcomes. Other trials are designed for lung cancer patients who have not responded adequately to conventional treatments. Your Lung Cancer Center oncologist will discuss the options and risks, and explain the various protocols involved.

How does CTCA select the trials it offers?

At CTCA, our Lung Cancer Center experts never stop searching for innovative ways to treat lung cancer. Offering carefully selected clinical trials helps us fulfill that mission. The new generation of precision drugs is generally designed to deliver more targeted, less toxic therapies. Our Lung Cancer Center oncologists decide to participate as a clinical trial site only after careful consideration of the relative benefit to patients.

Who may benefit from lung cancer clinical trials?

The answer is based on a case-by-case analysis of each lung cancer patient. This is a time of rapid scientific advances in lung cancer treatment. New surgical techniques are being developed with a goal of attacking lung tumors while reducing the amount of trauma to healthy tissue. Meanwhile, a new generation of lung cancer therapies is designed to attack tumors that have specific genomic mutations. These new targeted treatments may be more effective and cause fewer side effects than traditional chemotherapy. But they are so specialized that only a limited subset of lung cancer patients qualifies for participation. The immunotherapy drug nivolumab, for example, is approved for patients with non-squamous non-small cell lung cancer who have already tried platinum-based chemotherapy or EGFR- or ALK-targeted agents. Genomic tumor testing may determine whether you are a candidate. Other factors—such as your cancer mutations and stage, how you have responded to past treatments and other individual considerations—may also determine whether you qualify for specific trials.

How do I find out whether a specific clinical trial may benefit me?

Your Lung Cancer Center oncologist and care team may recommend a trial depending on your individual needs and treatment goals. Learn more about ongoing clinical trials at CTCA. For general questions, contact an Oncology Information Specialist at 888-841-9129.

Hospitals
HOSPITALS
Cancer Types
CANCER TYPE
Our Doctors
OUR DOCTORS
INSURANCE
INSURANCE